These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 16395703)

  • 41. C-reactive protein levels, variation in the C-reactive protein gene, and cancer risk: the Rotterdam Study.
    Siemes C; Visser LE; Coebergh JW; Splinter TA; Witteman JC; Uitterlinden AG; Hofman A; Pols HA; Stricker BH
    J Clin Oncol; 2006 Nov; 24(33):5216-22. PubMed ID: 17114654
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Multiple melanomas after treatment for Hodgkin lymphoma in a non-Dutch p16-Leiden mutation carrier with 2 MC1R high-risk variants.
    Figl A; Thirumaran RK; Ugurel S; Gast A; Hemminki K; Kumar R; Schadendorf D
    Arch Dermatol; 2007 Apr; 143(4):495-9. PubMed ID: 17438182
    [TBL] [Abstract][Full Text] [Related]  

  • 43. MC1R, ASIP, and DNA repair in sporadic and familial melanoma in a Mediterranean population.
    Landi MT; Kanetsky PA; Tsang S; Gold B; Munroe D; Rebbeck T; Swoyer J; Ter-Minassian M; Hedayati M; Grossman L; Goldstein AM; Calista D; Pfeiffer RM
    J Natl Cancer Inst; 2005 Jul; 97(13):998-1007. PubMed ID: 15998953
    [TBL] [Abstract][Full Text] [Related]  

  • 44. CDKN2A deletion in pediatric versus adult glioblastomas and predictive value of p16 immunohistochemistry.
    Purkait S; Jha P; Sharma MC; Suri V; Sharma M; Kale SS; Sarkar C
    Neuropathology; 2013 Aug; 33(4):405-12. PubMed ID: 23311918
    [TBL] [Abstract][Full Text] [Related]  

  • 45. CDKN2A as a uveal and cutaneous melanoma susceptibility gene.
    Kannengiesser C; Avril MF; Spatz A; Laud K; Lenoir GM; Bressac-de-Paillerets B
    Genes Chromosomes Cancer; 2003 Nov; 38(3):265-8. PubMed ID: 14506702
    [TBL] [Abstract][Full Text] [Related]  

  • 46. MC1R variation and melanoma risk in relation to host/clinical and environmental factors in CDKN2A positive and negative melanoma patients.
    Ghiorzo P; Bonelli L; Pastorino L; Bruno W; Barile M; Andreotti V; Nasti S; Battistuzzi L; Grosso M; Bianchi-Scarrà G; Queirolo P
    Exp Dermatol; 2012 Sep; 21(9):718-20. PubMed ID: 22804906
    [TBL] [Abstract][Full Text] [Related]  

  • 47. CDKN2A is the main susceptibility gene in Italian pancreatic cancer families.
    Ghiorzo P; Fornarini G; Sciallero S; Battistuzzi L; Belli F; Bernard L; Bonelli L; Borgonovo G; Bruno W; De Cian F; Decensi A; Filauro M; Faravelli F; Gozza A; Gargiulo S; Mariette F; Nasti S; Pastorino L; Queirolo P; Savarino V; Varesco L; Scarrà GB;
    J Med Genet; 2012 Mar; 49(3):164-70. PubMed ID: 22368299
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Glutathione S-transferase P1 and NADPH quinone oxidoreductase polymorphisms are associated with aberrant promoter methylation of P16(INK4a) and O(6)-methylguanine-DNA methyltransferase in sputum.
    Gilliland FD; Harms HJ; Crowell RE; Li YF; Willink R; Belinsky SA
    Cancer Res; 2002 Apr; 62(8):2248-52. PubMed ID: 11956078
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Frequent deletion and methylation in SH3GL2 and CDKN2A loci are associated with early- and late-onset breast carcinoma.
    Sinha S; Chunder N; Mukherjee N; Alam N; Roy A; Roychoudhury S; Kumar Panda C
    Ann Surg Oncol; 2008 Apr; 15(4):1070-80. PubMed ID: 18239974
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Some molecular and clinical aspects of genetic predisposition to malignant melanoma and tumours of various site of origin.
    Debniak T
    Hered Cancer Clin Pract; 2007 Jun; 5(2):97-116. PubMed ID: 19725989
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Lung Cancer in Poland.
    Adamek M; Biernat W; Chorostowska-Wynimko J; Didkowska JA; Dziadziuszko K; Grodzki T; Jassem J; Kępka L; Kowalski D; Krawczyk P; Krzakowski M; Nikliński J; Langfort R; Olszewski W; Orłowski T; Ramlau R; Rzyman W; Wrona A; Zieliński M; Dziadziuszko R
    J Thorac Oncol; 2020 Aug; 15(8):1271-1276. PubMed ID: 32718535
    [No Abstract]   [Full Text] [Related]  

  • 52. Deciphering Glioblastoma: Fundamental and Novel Insights into the Biology and Therapeutic Strategies of Gliomas.
    Onciul R; Brehar FM; Toader C; Covache-Busuioc RA; Glavan LA; Bratu BG; Costin HP; Dumitrascu DI; Serban M; Ciurea AV
    Curr Issues Mol Biol; 2024 Mar; 46(3):2402-2443. PubMed ID: 38534769
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clinical Significance of Gene Mutations and Polymorphic Variants and their Association with Prostate Cancer Risk in Polish Men.
    Heise M; Jarzemski P; Nowak D; Bąk A; Junkiert-Czarnecka A; Pilarska-Deltow M; Borysiak M; Pilarska B; Haus O
    Cancer Control; 2022; 29():10732748211062342. PubMed ID: 35638715
    [No Abstract]   [Full Text] [Related]  

  • 54. The association between single nucleotide polymorphisms and ovarian cancer risk: A systematic review and network meta-analysis.
    Hu J; Xu Z; Ye Z; Li J; Hao Z; Wang Y
    Cancer Med; 2023 Jan; 12(1):541-556. PubMed ID: 35637613
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Bladder cancer survival in patients with
    Złowocka-Perłowska E; van de Wetering T; Tołoczko-Grabarek A; Scott RJ; Lubiński J
    Oncotarget; 2022; 13():628-640. PubMed ID: 35478773
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Integrative genomic analysis focused on cell cycle genes for MYC-driven aggressive mature B-cell lymphoma.
    Yamashita T; Vollbrecht C; Hirsch B; Kleo K; Anagnostopoulos I; Hummel M
    J Clin Exp Hematop; 2020; 60(3):87-96. PubMed ID: 32981916
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Analysis of CDKN2A gene alterations in recurrent and non-recurrent meningioma.
    Guyot A; Duchesne M; Robert S; Lia AS; Derouault P; Scaon E; Lemnos L; Salle H; Durand K; Labrousse F
    J Neurooncol; 2019 Dec; 145(3):449-459. PubMed ID: 31729637
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Genetic polymorphisms may influence the vertical growth rate of melanoma.
    Sikora M; Rudnicka L; Borkowska B; Kardynał A; Słowińska M; Rakowska A; Warszawik-Hendzel O; Wiergowska A; Ługowska I; Rutkowski P; Dębniak T; Lubiński J; Olszewska M
    J Cancer; 2018; 9(17):3078-3083. PubMed ID: 30210630
    [No Abstract]   [Full Text] [Related]  

  • 59. Cumulative Small Effect Genetic Markers and the Risk of Colorectal Cancer in Poland, Estonia, Lithuania, and Latvia.
    Serrano-Fernandez P; Dymerska D; Kurzawski G; Derkacz R; Sobieszczańska T; Banaszkiewicz Z; Roomere H; Oitmaa E; Metspalu A; Janavičius R; Elsakov P; Razumas M; Petrulis K; Irmejs A; Miklaševičs E; Scott RJ; Lubiński J
    Gastroenterol Res Pract; 2015; 2015():204089. PubMed ID: 26101521
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Significance of CDKN2A gene A148T variant in patients with bladder cancer.
    Borkowska E; Jędrzejczyk A; Kruk A; Pietrusiński M; Traczyk M; Rożniecki M; Kałużewski B
    Cent European J Urol; 2011; 64(3):168-74. PubMed ID: 24578887
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.